Developer docs
API playgroundTry for free, no card

Search company profiles

Cell X Technologies

Full company profile

uuid0000ct1

Namestring
Cell X Technologies
Legal namestring
Cell X Technologies
Company typeenum
Private
Founded yearint
2023
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCleveland, United States
HQ citystring
Cleveland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell processing automation, GMP cell manufacturing, iPSC manufacturing platform, robotic cell handling, cell therapy automation
Industry3 codes
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Cell Therapy Manufacturing Automation
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Celligent Platform Licensing and Services
TypeSubscription Recurring
Description

Cell X Technologies generates revenue through licensing its Celligent automation platform and providing associated services for cell therapy manufacturing. The platform supports both autologous and allogeneic cell therapies, as well as tissue engineering and artificial organ applications.

cellxtechnologies.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cell X Technologies sells and licenses the Celligent™ Cell Processing Platform, an integrated system combining proprietary robotics, imaging, and artificial intelligence that automates GMP-compliant manufacturing of autologous and allogeneic cell therapies, stem cell-derived therapies, tissue engineering, and artificial organ applications. The platform delivers automated handling and selection, machine learning-driven process optimization via the CxKnowledge data bank, and 21 CFR Part 11 compliant data collection that supports IND filings.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduces operator-dependent variability in iPSC culture and differentiation
+2 more records
Product overview1 text field

Cell X Technologies offers a single unified product—the Celligent™ platform—which combines robotics, imaging, and artificial intelligence into one integrated cell processing solution. The platform enables scalable, GMP-compliant manufacturing workflows for cell therapies, stem cell-derived therapies, tissue engineering, and artificial organ applications. Key capabilities include BioAdaptive Automation for automated handling and selection, machine learning-driven process optimization via the CxKnowledge data bank, and comprehensive data collection for regulatory filings including IND submissions.

Product and service1 record
1Celligent™ Cell Processing Platform
CategoryCell therapy manufacturing automation
Description

Integrated robotic, imaging, and AI-driven cell processing platform that automates GMP-compliant manufacturing workflows for cellular therapies, stem cell-derived therapies, tissue engineering, and artificial organ applications; targeted at cell therapy developers and biopharma innovators requiring reproducible, IND-ready cell processing.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-29
Description

Cell X Technologies announced a collaboration with BioLamina to integrate BioLamina's defined laminin reagents with Cell X's Celligent automation platform for advanced therapy manufacturing. The partnership aims to reduce operator-dependent variability and enhance reproducibility in iPSC culture and differentiation, targeting scalable, GMP-compliant workflows for next-generation cell therapies. The collaboration combines Cell X's walk-away automation and imaging capabilities with BioLamina's full-length human recombinant laminin-521 and laminin-511 reagents.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cellares develops the Cell Shuttle, an automated cell therapy manufacturing platform integrating robotics and software for GMP-compliant production. It directly competes with Celligent in the iPSC and cell therapy automation space, targeting the same developer customer base with a similar end-to-end value proposition.

TypeDirect peer
Description

Ori Biotech builds the IRO platform, a closed, automated cell and gene therapy manufacturing system combining hardware, software, and analytics. It is a direct competitor in cell therapy process automation, addressing the same scalability and reproducibility pain points Cell X targets.

TypeDirect peer
Description

Multiply Labs produces robotic manufacturing systems for cell therapies and personalized medicines, including iPSC-derived products. It overlaps with Cell X on robotics-driven cell processing automation and targets a similar cell therapy developer customer base.

TypeBroad incumbent
Description

Cytiva (a Danaher company) offers a broad portfolio of cell therapy manufacturing tools, automation, and services including the Sefia and Xuri cell expansion systems. As a large incumbent, it competes with Cell X in cell therapy automation while also serving as a potential partner or acquirer.

TypeBroad incumbent
Description

Lonza is a global CDMO and process development leader with significant cell and gene therapy manufacturing automation capabilities. It is a broad incumbent addressing the same customers as Cell X, both as a potential competitor for automation technology and as a partner via CDMO relationships.

TypeBroad incumbent
Description

Miltenyi Biotec provides cell processing instruments, reagents, and GMP-compliant manufacturing solutions for cell and gene therapy. It overlaps with Cell X on automated cell handling and serves the same therapeutic developer customers, though with a much broader portfolio.

TypeBroad incumbent
Description

Thermo Fisher offers cell therapy manufacturing platforms, including the Gibco CTS product line and the Cell Therapy Systems (CTS) DynaMag family. It is a broad incumbent competitor and potential partner addressing GMP-compliant cell processing workflows.

TypeEmerging player
Description

bit.bio operates an iPSC cell programming platform (io Cells) with an integrated manufacturing approach combining biology and automation. It intersects with Cell X as both a potential customer (cell therapy developer needing automation) and a competitor in standardized iPSC workflows.

TypeEmerging player
Description

Stemcell Technologies provides cell culture media, instruments, and automation tools for cell therapy and regenerative medicine research. It overlaps with Cell X in serving stem cell researchers and developers with workflow automation tooling.

TypeBroad incumbent
Description

Sartorius offers bioprocessing and cell analytics automation products used in cell therapy manufacturing, including the Incucyte live-cell imaging platform. It competes with Cell X at the intersection of automated cell processing, imaging, and GMP workflow support.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cell X Technologies

Cell Therapy Manufacturing Automationcellxtechnologies.com

Cell X Technologies firmographics

Firmographics
Name
Cell X Technologies
Legal name
Cell X Technologies
Website
https://cellxtechnologies.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Cell X Technologies industry classification

Industry
Product category
Cell Therapy Manufacturing Automation
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Cell processing automation
  • GMP cell manufacturing
  • IPSC manufacturing platform
  • Robotic cell handling
  • Cell therapy automation

Where Cell X Technologies is headquartered

Location

Headquarters

HQ city
Cleveland
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cell X Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Celligent Platform Licensing and Services: Cell X Technologies generates revenue through licensing its Celligent automation platform and providing associated services for cell therapy manufacturing. The platform supports both autologous and allogeneic cell therapies, as well as tissue engineering and artificial organ applications.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Cell X Technologies product offering

Product offering

Core offering

Cell X Technologies sells and licenses the Celligent™ Cell Processing Platform, an integrated system combining proprietary robotics, imaging, and artificial intelligence that automates GMP-compliant manufacturing of autologous and allogeneic cell therapies, stem cell-derived therapies, tissue engineering, and artificial organ applications. The platform delivers automated handling and selection, machine learning-driven process optimization via the CxKnowledge data bank, and 21 CFR Part 11 compliant data collection that supports IND filings.

Product overview

Cell X Technologies offers a single unified product—the Celligent™ platform—which combines robotics, imaging, and artificial intelligence into one integrated cell processing solution. The platform enables scalable, GMP-compliant manufacturing workflows for cell therapies, stem cell-derived therapies, tissue engineering, and artificial organ applications. Key capabilities include BioAdaptive Automation for automated handling and selection, machine learning-driven process optimization via the CxKnowledge data bank, and comprehensive data collection for regulatory filings including IND submissions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Celligent™ Cell Processing Platform Integrated robotic, imaging, and AI-driven cell processing platform that automates GMP-compliant manufacturing workflows for cellular therapies, stem cell-derived therapies, tissue engineering, and artificial organ applications; targeted at cell therapy developers and biopharma innovators requiring reproducible, IND-ready cell processing.

Quantifiable outcome

  • Reduces operator-dependent variability in iPSC culture and differentiation
  • +2 more outcomes

Companies that use Cell X Technologies

Customer profile

Segments4 records

Ideal customer profiles3 records

Cell X Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Cell X Technologies partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BioLaminacoreStrategic or Co-development Partner · 29 September 2025Cell X Technologies announced a collaboration with BioLamina to integrate BioLamina's defined laminin reagents with Cell X's Celligent automation platform for advanced therapy manufacturing. The partnership aims to reduce operator-dependent variability and enhance reproducibility in iPSC culture and differentiation, targeting scalable, GMP-compliant workflows for next-generation cell therapies. The collaboration combines Cell X's walk-away automation and imaging capabilities with BioLamina's full-length human recombinant laminin-521 and laminin-511 reagents.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Cell X Technologies competitors and assessment

Company assessment

Direct peers

  • Cellares: Cellares develops the Cell Shuttle, an automated cell therapy manufacturing platform integrating robotics and software for GMP-compliant production. It directly competes with Celligent in the iPSC and cell therapy automation space, targeting the same developer customer base with a similar end-to-end value proposition.
  • Ori Biotech: Ori Biotech builds the IRO platform, a closed, automated cell and gene therapy manufacturing system combining hardware, software, and analytics. It is a direct competitor in cell therapy process automation, addressing the same scalability and reproducibility pain points Cell X targets.
  • Multiply Labs: Multiply Labs produces robotic manufacturing systems for cell therapies and personalized medicines, including iPSC-derived products. It overlaps with Cell X on robotics-driven cell processing automation and targets a similar cell therapy developer customer base.

Broad incumbents

  • Cytiva: Cytiva (a Danaher company) offers a broad portfolio of cell therapy manufacturing tools, automation, and services including the Sefia and Xuri cell expansion systems. As a large incumbent, it competes with Cell X in cell therapy automation while also serving as a potential partner or acquirer.
  • Lonza Cell & Gene Technologies: Lonza is a global CDMO and process development leader with significant cell and gene therapy manufacturing automation capabilities. It is a broad incumbent addressing the same customers as Cell X, both as a potential competitor for automation technology and as a partner via CDMO relationships.
  • Miltenyi Biotec: Miltenyi Biotec provides cell processing instruments, reagents, and GMP-compliant manufacturing solutions for cell and gene therapy. It overlaps with Cell X on automated cell handling and serves the same therapeutic developer customers, though with a much broader portfolio.
  • Thermo Fisher Scientific (Cell Therapy): Thermo Fisher offers cell therapy manufacturing platforms, including the Gibco CTS product line and the Cell Therapy Systems (CTS) DynaMag family. It is a broad incumbent competitor and potential partner addressing GMP-compliant cell processing workflows.
  • Sartorius (Cell Analytics & Automation): Sartorius offers bioprocessing and cell analytics automation products used in cell therapy manufacturing, including the Incucyte live-cell imaging platform. It competes with Cell X at the intersection of automated cell processing, imaging, and GMP workflow support.

Emerging players

  • bit.bio: bit.bio operates an iPSC cell programming platform (io Cells) with an integrated manufacturing approach combining biology and automation. It intersects with Cell X as both a potential customer (cell therapy developer needing automation) and a competitor in standardized iPSC workflows.
  • Stemcell Technologies: Stemcell Technologies provides cell culture media, instruments, and automation tools for cell therapy and regenerative medicine research. It overlaps with Cell X in serving stem cell researchers and developers with workflow automation tooling.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights7 records

Customer concentration

Cell X Technologies social profiles

Digital presence

Cell X Technologies compliance and trust

Trust signal

Compliance1 record

Cell X Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cell X Technologies leadership team

Management profile

Number of profiles

Profiles6 records

Cell X Technologies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cell X Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cell X Technologies

What does Cell X Technologies do?

Cell X Technologies sells and licenses the Celligent™ Cell Processing Platform, an integrated system combining proprietary robotics, imaging, and artificial intelligence that automates GMP-compliant manufacturing of autologous and allogeneic cell therapies, stem cell-derived therapies, tissue engineering, and artificial organ applications. The platform delivers automated handling and selection, machine learning-driven process optimization via the CxKnowledge data bank, and 21 CFR Part 11 compliant data collection that supports IND filings.

Is Cell X Technologies a public or private company?

Cell X Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cell X Technologies founded?

Cell X Technologies was founded in 2023. It employs 11 to 50 people.

Where is Cell X Technologies based?

Cell X Technologies is headquartered in Cleveland, United States, in the North America region.

How does Cell X Technologies make money?

One revenue line is on record: celligent Platform Licensing and Services.

Who are Cell X Technologies's main competitors?

Direct peers on record are Cellares, Ori Biotech and Multiply Labs. Broad incumbents are Cytiva, Lonza Cell & Gene Technologies, Miltenyi Biotec, Thermo Fisher Scientific (Cell Therapy) and Sartorius (Cell Analytics & Automation). Emerging players are bit.bio and Stemcell Technologies.

Does Cell X Technologies have an API?

No public API is recorded for Cell X Technologies.

What industry is Cell X Technologies in?

Cell X Technologies's product category is Cell Therapy Manufacturing Automation. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeuticsCell X Technologies announced a collaboration with BioLamina to integrate BioLamina's defined laminin reagents with Cell X's Celligent automation platform for advanced therapy manufacturing. The partnership aims to reduce operator-dependent variability and enhance reproducibility in iPSC culture and differentiation, targeting scalable, GMP-compliant workflows for next-generation cell therapies. The collaboration combines Cell X's walk-away automation and imaging capabilities with BioLamina's full-length human recombinant laminin-521 and laminin-511 reagents.PR NewswireCell X Technologies and Aspen Neuroscience collaborate to address throughput and scalability in manufacturing automation to facilitate iPSC cell processing.Cell X Technologies and Aspen Neuroscience signed a collaboration and licensing agreement to provide automated cell processing for Aspen's iPSC-derived autologous clinical manufacturing. The agreement targets throughput and scalability in manufacturing automation to facilitate iPSC cell processing for Parkinson's disease treatment.PR NewswireAspen Neuroscience Announces Collaboration and License Agreement with Cell X TechnologiesAspen Neuroscience and Cell X Technologies signed a collaboration and license agreement to automate iPSC production for its autologous cell therapy platform. Aspen will lead discovery and commercialization, while Cell X will develop its Celligent platform. The partnership aims to scale automated manufacturing for personalized cell therapies, including ANPD001 for Parkinson's disease.